Skip to main content
Premium Trial:

Request an Annual Quote

Genomics One Closes $500K Private Placement to Finance BioDefense Operations

NEW YORK, June 3 (GenomeWeb News) - Genomics One announced today a $500,000 private placement financing for its biodefense operations.


Genomics One CEO Suzanne Lebel will sell to Wyntrust Ventures Capital 1.2 million common shares of Genomics One stock at a price of $.23 per share for gross proceeds of $272,727. In addition, a second investor will subscribe 1 million common shares at $.23 per share for gross proceeds of $227,273.


The transaction is subject to TSX Venture Exchange approval, and is expected to close on or about June 8.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.